Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNotebook: Xencor regains rights from Amgen; plus three other deals

This article was originally published in Scrip

Executive Summary

Xencor gains greater control in Amgen pact; Zogenix buys Brabant Pharma; CTI BioPharma buys worldwide rights to tosedostat; and Takeda licenses Mersana ADC.

You may also be interested in...



Xencor's Coming Share Issue To Help Fund Immuno-Oncology Pipeline

Monrovia, California-based Xencor Inc.'s latest funding exercise is a public share offering to raise some $110m after expenses to advance its immuno-oncology pipeline.

Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees

Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.

With $850m, Nuvation Aims To Speed Novel Cancer Drugs To Patients

Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel